In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.

SAN DIEGO, April 3, 2012 /PRNewswire/ -- Cylene Pharmaceuticals, Inc.

Later-stage cancers thrive by finding detours around roadblocks that cancer drugs put in their path, but a Purdue University biochemist is creating maps that will help drugmakers close more routes and develop better drugs.

Later-stage cancers thrive by finding detours around roadblocks that cancer drugs put in their path, but a Purdue University biochemist is creating maps that will help drugmakers close more routes and develop better drugs.

LONDON, December 7, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference